Generation of mAbs against the genotype 3a of HCV (prevalent in India).
Neutralizing mAbs significantly inhibit virus binding and entry to hepatoma cells.
Epitopes recognised by the mAbs are unique, distinct and non-overlapping.
Combination of the mAbs significantly prevent viral (JFH1 strain) infection ex vivo.